Platelet-rich plasma: support for its use in wound healing

Yale J Biol Med. 2010 Mar;83(1):1-9.


Previous topical growth factor studies have shown that recombinant human platelet-derived growth factor-BB isomer (rhPDGF-BB) is an efficacious treatment of chronic diabetic foot ulceration. A newer treatment, autologous platelet-rich plasma (PRP), represents a greater similarity to the natural healing process as a composite of multiple growth factors, is safe due to its autologous nature, and is produced as needed from patient blood. A review of the literature shows few studies performed with scientific rigor, although the safety of PRP appears to be validated. As the use of PRP increases, additional studies may establish PRP as an efficacious treatment modality and guide future treatment of chronic diabetic foot ulceration.

Keywords: autologous; diabetic foot; platelet-rich plasma; therapy; ulcer; wound healing; wounds.

Publication types

  • Review

MeSH terms

  • Becaplermin
  • Blood Transfusion, Autologous
  • Clinical Trials as Topic
  • Diabetic Foot / drug therapy
  • Humans
  • Platelet-Derived Growth Factor / therapeutic use
  • Platelet-Rich Plasma* / metabolism
  • Proto-Oncogene Proteins c-sis
  • Wound Healing*


  • Platelet-Derived Growth Factor
  • Proto-Oncogene Proteins c-sis
  • Becaplermin